At a glance
- Originator Teijin Pharma
- Class Benzoic acids
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Allergic asthma
Most Recent Events
- 19 Oct 2000 Discontinued-Preclinical for Allergic asthma in Japan (Unknown route)
- 14 Sep 1999 Preclinical development for Allergic asthma in Japan (Unknown route)